1-13 of 13
Jeffrey A. Engelman
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Tumor Intrinsic Efficacy by SHP2 and RTK Inhibitors in KRAS-Mutant Cancers

Free
Huai-Xiang Hao, Hongyun Wang, Chen Liu, Steven Kovats, Roberto Velazquez, Hengyu Lu, Bhavesh Pant, Matthew Shirley, Matthew J. Meyer, Minying Pu, Joanne Lim, Michael Fleming, LeighAnn Alexander, Ali Farsidjani, Matthew J. LaMarche, Susan Moody, Serena J. Silver, Giordano Caponigro, Darrin D. Stuart, Tinya J. Abrams, Peter S. Hammerman, Juliet Williams, Jeffrey A. Engelman, Silvia Goldoni, Morvarid Mohseni
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2019) 18 (12): 2368–2380.
https://doi.org/10.1158/1535-7163.MCT-19-0170
Published: 02 December 2019
View articletitled, Tumor Intrinsic Efficacy by SHP2 and RTK Inhibitors in KRAS-Mutant Cancers
Open the PDF for Tumor Intrinsic Efficacy by SHP2 and RTK Inhibitors in KRAS-Mutant Cancers in another window
Includes: Supplementary data
Journal Articles

Abstract A122: Molecular barcoding and single cell approaches to investigate drug tolerance in EGFRmut NSCLC

Free
Jennifer L. Cotton, Viveksagar KrishnamurthyRadhakrishna, Julie Chen, Michelle Piquet, Joel Wagner, Gaylor Boulay, Kathleen Sprouffske, Youngchul Song, Xiaoyan Li, Katja Schumacher, Raphael Thierry, Nathaniel D. Kirkpatrick, David A. Ruddy, Joshua Korn, Erick J. Morris, Peter S. Hammerman, Jeffrey A. Engelman, Matthew J. Niederst
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2019) 18 (12_Supplement): A122.
https://doi.org/10.1158/1535-7163.TARG-19-A122
Published: 01 December 2019
View articletitled, Abstract A122: Molecular barcoding and single cell approaches to investigate drug tolerance in EGFRmut NSCLC
Journal Articles

SHP2 Inhibition Overcomes RTK-Mediated Pathway Reactivation in KRAS-Mutant Tumors Treated with MEK Inhibitors

Free
Hengyu Lu, Chen Liu, Roberto Velazquez, Hongyun Wang, Lukas Manuel Dunkl, Malika Kazic-Legueux, Anne Haberkorn, Eric Billy, Eusebio Manchado, Saskia M. Brachmann, Susan E. Moody, Jeffrey A. Engelman, Peter S. Hammerman, Giordano Caponigro, Morvarid Mohseni, Huai-Xiang Hao
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2019) 18 (7): 1323–1334.
https://doi.org/10.1158/1535-7163.MCT-18-0852
Published: 01 July 2019
View articletitled, SHP2 Inhibition Overcomes RTK-Mediated Pathway Reactivation in KRAS-Mutant Tumors Treated with MEK Inhibitors
Open the PDF for SHP2 Inhibition Overcomes RTK-Mediated Pathway Reactivation in KRAS-Mutant Tumors Treated with MEK Inhibitors in another window
Includes: Supplementary data
Journal Articles

Abstract B96: Adaptive resistance to therapeutic PD-1:PD-L1 blockade is mediated by upregulation of the TIM-3 immune checkpoint

Free
Esra A. Akbay, Shohei Koyama, Yvonne Y. Li, Grit S. Herter-Sprie, Kevin A. Buczkowski, William G. Richards, Leena Gandhi, Amanda J. Redig, Scott J. Rodig, Hajime Asahina, Robert E. Jones, Meghana M. Kulkarni, Peter E. Fecci, Bruce E. Johnson, Pasi A. Janne, Jeffrey A. Engelman, Sidharta P. Gangadharan, Daniel B. Costa, Gordon J. Freeman, Raphael Bueno, F. Stephen Hodi, Glenn Dranoff, Kwok-Kin Wong, Peter S. Hammerman
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2015) 14 (12_Supplement_2): B96.
https://doi.org/10.1158/1535-7163.TARG-15-B96
Published: 01 December 2015
View articletitled, Abstract B96: Adaptive resistance to therapeutic PD-1:PD-L1 blockade is mediated by upregulation of the TIM-3 immune checkpoint
Journal Articles

Abstract PR09: Synthetic lethal interaction of combined BCL-XL and MEK inhibition promotes tumor regressions in KRAS-mutant cancer models

Free
Ryan B. Corcoran, Katherine A. Cheng, Aaron N. Hata, Anthony C. Faber, Hiromichi Ebi, Erin M. Coffee, Patricia Greninger, Ronald D. Brown, Jason T. Godfrey, Travis J. Cohoon, Youngchul Song, Eugene Lifshits, Toshi Shioda, Dora Dias-Santagata, Anurag Singh, Jeffrey Settleman, Cyril H. Benes, Mari Mino-Kenudson, Kwok-Kin Wong, Jeffrey A. Engelman
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2013) 12 (5_Supplement): PR09.
https://doi.org/10.1158/1535-7163.PMS-PR09
Published: 01 May 2014
View articletitled, Abstract PR09: Synthetic lethal interaction of combined BCL-XL and MEK inhibition promotes tumor regressions in KRAS-mutant cancer models
Journal Articles

Abstract C137: Rapid assessment of TORC1 suppression as a functional biomarker predicting responsiveness to RAF and MEK inhibitors in BRAF-mutant melanoma patients.

Free
Ryan B. Corcoran, S. Michael Rothenberg, Aaron N. Hata, Anthony C. Faber, Adriano Piris, Rosalynn M. Nazarian, Ronald D. Brown, Jason T. Godfrey, Daniel Winokur, John Walsh, Mari Mino-Kenudson, Shyamala Maheswaran, Jeffrey Settleman, Jennifer A. Wargo, Keith T. Flaherty, Daniel A. Haber, Jeffrey A. Engelman
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2013) 12 (11_Supplement): C137.
https://doi.org/10.1158/1535-7163.TARG-13-C137
Published: 01 November 2013
View articletitled, Abstract C137: Rapid assessment of TORC1 suppression as a functional biomarker predicting responsiveness to RAF and MEK inhibitors in BRAF-mutant melanoma patients.
Journal Articles

Abstract A29: PI3K regulates MEK/ERK signaling in breast cancer via the Rac-GEF, P-Rex1.

Free
Hiromichi Ebi, Carlotta Costa, Anthony Faber, Dejan Juric, Patricia Della Pelle, Youngchul Song, Seiji Yano, Mari Mino-Kenudson, Cyril H. Benes, Jeffrey A. Engelman
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2013) 12 (11_Supplement): A29.
https://doi.org/10.1158/1535-7163.TARG-13-A29
Published: 01 November 2013
View articletitled, Abstract A29: PI3K regulates MEK/ERK signaling in breast cancer via the Rac-GEF, P-Rex1.
Journal Articles

Abstract A87: Overcoming NSCLC to SCLC transformation as a resistance mechanism in EGFR mutant lung cancer.

Free
Matthew J. Niederst, Lecia V. Sequist, Elizabeth L. Lockerman, Carlotta Costa, Darrell R. Borger, Mari Mino-Kenudson, Anthony J. Iafrate, Jeffrey A. Engelman
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2013) 12 (11_Supplement): A87.
https://doi.org/10.1158/1535-7163.TARG-13-A87
Published: 01 November 2013
View articletitled, Abstract A87: Overcoming NSCLC to SCLC transformation as a resistance mechanism in EGFR mutant lung cancer.
Journal Articles

Abstract B186: The unexpected role of p110β in HER2 amplified and PIK3CA mutant breast cancers.

Free
Carlotta Costa, Hiromichi Ebi, Anthony C. Faber, Madhuri Nishtala, Young Chul Song, Jeffrey A. Engelman
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2013) 12 (11_Supplement): B186.
https://doi.org/10.1158/1535-7163.TARG-13-B186
Published: 01 November 2013
View articletitled, Abstract B186: The unexpected role of p110β in HER2 amplified and PIK3CA mutant breast cancers.
Journal Articles

Abstract B106: mTORC1 inhibition is required for sensitivity to PI3K p110α inhibitors in PIK3CA-mutant breast cancer.

Free
Moshe Elkabets, Sadhna Vora, Dejan Juric, Natasha Morse, Mari Mino-Kenudson, Taru Muranen, Jessica Tao, Ana Bosch Campos, Jordi Rodon, Yasir H. Ibrahim, Violeta Serra, Vanessa Rodrik-Outmezguine, Saswati Hazra, Sharat Singh, Phillip Kim, Cornelia Quadt, Liu Manway, Alan Huang, Neal Rosen, Jeffrey A. Engelman, Maurizio Scaltriti, José Baselga
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2013) 12 (11_Supplement): B106.
https://doi.org/10.1158/1535-7163.TARG-13-B106
Published: 01 November 2013
View articletitled, Abstract B106: mTORC1 inhibition is required for sensitivity to PI3K p110α inhibitors in PIK3CA-mutant breast cancer.
Journal Articles

Abstract C263: mTOR inhibition specifically sensitizes colorectal cancers with KRAS or BRAF mutations to BCL-2/BCL-XL inhibition by suppressing MCL-1.

Free
Erin M. Coffee, Anthony C. Faber, Carlotta Costa, Anahita Dastur, Hiromichi Ebi, Aaron N. Hata, Alan T. Yeo, Elena J, Youngchul Song, Ah Ting Tam, Jessica L. Boisvert, Randy J. Milano, Jatin Roper, David P. Kodack, Rakesh K. Jain, Ryan B. Corcoran, Miguel N. Rivera, Sridhar Ramaswamy, Kenneth E. Hung, Cyril H. Benes, Jeffrey A. Engelman
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2013) 12 (11_Supplement): C263.
https://doi.org/10.1158/1535-7163.TARG-13-C263
Published: 01 November 2013
View articletitled, Abstract C263: mTOR inhibition specifically sensitizes colorectal cancers with KRAS or BRAF mutations to BCL-2/BCL-XL inhibition by suppressing MCL-1.
Journal Articles

Abstract B103: Integrative genomic and proteomic analyses identify novel targets for Lkb1 deficient metastatic lung tumors

Free
Julian Carretero, Takeshi Shimamura, Klarisa Rikova, Ting‐Lei Gu, Christa L. Borgman, S. Buttarazzi, Kate L. McNamara, Kathleyn A. Brandstetter, Jeffrey C. Silva, Geoffrey I. Shapiro, Diego H. Castrillon, Michel Maira, Carlos García‐Echeverría, Carla F. Kim, Nabeel Bardeesy, Norman E. Sharpless, William Y. Kim, Jeffrey A. Engelman, Kwok K. Wong
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2009) 8 (12_Supplement): B103.
https://doi.org/10.1158/1535-7163.TARG-09-B103
Published: 10 December 2009
View articletitled, Abstract B103: Integrative genomic and proteomic analyses identify novel targets for Lkb1 deficient metastatic lung tumors
Journal Articles

Abstract A254: A phase 1 safety and pharmacokinetic (PK) study of PI3K/TORC1/TORC2 inhibitor, XL765 (SAR245409), in combination with erlotinib in patients (pts) with advanced solid tumors

Free
Pasi A. Janne, Enriqueta Felip, Susana Cedrés, Steven J. Cohen, Jeffrey A. Engelman, Joan Lucca, Pablo Martínez, Margaret von Mehren, Steven B. Gendreau, Katherine K. Lara, Jean‐Francois Martini, Roger B. Cohen
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2009) 8 (12_Supplement): A254.
https://doi.org/10.1158/1535-7163.TARG-09-A254
Published: 10 December 2009
View articletitled, Abstract A254: A phase 1 safety and pharmacokinetic (PK) study of PI3K/TORC1/TORC2 inhibitor, XL765 (SAR245409), in combination with erlotinib in patients (pts) with advanced solid tumors